A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
← catalyst calendarNCT06962800 · readout in 1,257 d
Sponsored by Biogen (industry) · BIIB — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
180estimated
Sites
111
Countries
Argentina, Australia, Brazil +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-22 | actual | When the study began enrolling |
| Primary completion | 2030-01-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-01-17 | estimated | The whole study's end, after follow-up |
| First posted | 2025-05-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Membranous Nephropathy
Interventions
- Drug: Felzartamab — also filed as MOR202, MOR03087, TJ202, BIIB148, HIB202
- Drug: Tacrolimus
- Drug: Standard of Care IST
Primary outcome
what the primary-completion date above is the date OFPercentage of Participants who Achieve Complete Remission (CR) at Week 104
measured Week 104
Permalink · BIIB's whole pipeline · Catalyst calendar · Every registered study · What changed